For Boston Scientific, the growth cup is half full | Wall Street Beat

Wed, 09/12/2012 - 2:42pm
Mass Device

For executives at medical device company Boston Scientific, growing the non-stent and non-CRM business has become a priority – and a bright spot. Wall Street Beat

For Boston Scientific (NYSE:BSX), proving to Wall Street that it's still capable of growing sales is key to reviving its sagging share price, officials said today.

One way to prove to The Street that the Natick, Mass.-based medical device company hasn't lost its mojo is its non-stent and non-cardiac rhythm management businesses, incoming CEO Michael Mahoney said during a question-and-answer session at the Morgan Stanley Global Healthcare Investors conference in New York.

Mahoney said that the company's endoscopy, peripheral intervention and neuromodulation units are experiencing healthy growth, in contrast to the struggles facing the company's bread-and-butter stent and CRM operations. Boston Scientific will look to continue the growth trend for the non-core business units, he said.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.